## Index

Abbott, A. 131, 136, 168, 195  
adverse drug reaction (ADR) 41, 49  
reporting systems 54, 57, 67, 87, 91  
reports 7, 53, 59, 82, 91, 98, 156  
side-effects 5, 8, 12, 13, 16, 17, 37, 82, 83, 89, 91, 99, 107, 139, 142, 143, 148, 152, 153, 170, 183, 194, 195, 197, 203  
signal of 12, 38, 43, 67, 73, 75, 77, 82, 85, 87, 95, 154, 180, 181  
Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS) 83, 85  
American Medical Association (AMA) 67  
Bauman, Howard 114, 124–6, 131–2, 135  
Bayer 84, 85, 94  
Ben-David, J. 25  
boundary-organisations 34  
Bovine Spongiform Encephalopathy (BSE) 39, 44, 45, 46, 47, 70, 73, 165, 166  
Boyle, Robert 29, 32, 208  
Braithwaite, J. and Drahos, P. 8, 20  
Brunsson, N. 10, 18, 33  
Cambrosio, A. 214  
Carpenter, D. 17, 73  
Cerivastatin 84–6, 92–8, 106, 153, 194, 196, 205; *see also* Lipobay  
Chipping Campden 129  
circulation  
  as defining experts 32  
  as professional mobility 29  
  between activities of control 33  
  between evaluation and standard-setting 33  
invisibility of 11  
measurement of 28  
multi-professionalism and 169–71  
of drug safety experts 78, 99, 102, 107  
of HACCP experts 119, 137, 139–40  
of PMM experts 159, 161  
transnationalisation and 177–81  
clinical pharmacology  
as evaluative science 12, 37  
as experimental science 48–50; *see also* clinical trials  
co-word analysis of 57–8  
dose-response assessment and 48, 57, 58  
drug regulation in the USA and 66–7  
efficacy 48–50, 54, 58, 66, 67, 211, 212  
history of 74  
pharmacovigilance and 53  
statistics and 56  
clinical trials; *see also* marketing authorisation  
as experiment 48–50  
as tool of qualification 37  
clinical pharmacology and 74  
for functional or novel foods 143  
generalisation of 41  
limits of 53–9, 77, 90, 98  
safety data from 14, 102, 106  
Codex Alimentarius (Codex)  
as receptacle of expert work 125–30  
as standard setting organisation 33  
as WTO reference body 75  
Codex Committee on Food Hygiene 128, 129  
Codex principles for risk analysis and EU food law 70
consensus on HACCP and 134–40  
International guideline for HACCP  
14, 112–22  
members of ICMSF and 132  
risk assessment and 69  
setting of critical control points and  
129–30  
Committee for Proprietary Medicinal  
Products (CPMP) 41, 73, 88, 178;  
see also Committee for Human  
Medicinal Products (CHMP)  
Committee for the Safety of Drugs  
(CSD) 67  
Conference for the International  
Organization of Medical Sciences  
(CIOMS) 98, 101, 102–5, 108–9,  
167, 177, 178, 181–3, 186–7, 193,  
207; see also International  
Conference on Harmonisation  
(ICH)  
consensus  
consensus conferences 15, 169  
consensus, manufacturing of 11, 34,  
134, 135, 137, 187  
conventional foods 144, 145, 151,  
212  
Council of Ministers of the European  
Union 46  
co-word analysis 57, 61, 63, 213, 214  
Crane, D. 29–31, 34  
Crestor 153  
Daemmrich, A. 73  
development safety update report  
(DSUR) 102  
Directorate General XXIV 74; see also  
Directorate General for Health  
and Consumer Protection  
Directorate General for Health and  
Consumer Protection (DG  
SANCO) 45, 70, 161; see also DG  
XXIV  
Djelic, M.-L. and Sahlin-Andersson K.  
(eds.) 9  

drug safety  
CIOMS and ICH 178, 182, 183  
clinical pharmacology and 53  
clinical trials and 56–9  
drug safety and PVP 78–83  
drug safety experts 14, 86, 89, 92–4,  
98, 99, 102, 107–9, 173, 193,  
196–7, 201, 202, 205  
scientists’ conception of 66  
Drug Safety Research Unit (DSRU)  
86  
drug withdrawal  
as result of pharmacovigilance  
activities 72  
Cerivastatin 84–6, 88; see also  
Lipobay  
periodic safety update report and  
196  
PVP and avoidance of 12  
risk management and 94–7  
series of 77–8  
worldwide withdrawals of Vioxx and  
Lipobay 43  
due diligence 123, 138  

European Commission  
as international policy-making  
organisation 33  
CIOMS and 182  
European Medicines Evaluation  
Agency and 67  
HACCP and 113, 118–22, 128, 137,  
143  
New Approach 118, 119, 128  
Novel foods and 146, 147, 150, 153,  
155, 161, 165  
Elixir Sulfanilamide 39, 91  
European Medicines Evaluation  
Agency (EMEA); see also  
regulatory agencies  
creation of 41  
Gabriel and meetings at 177  
globalisation of pharmaceutical  
regulation and 209  
marketing authorisation decisions  
195  
pharmacovigilance missions 43  
risk management guidelines 78, 80,  
83, 84, 193, 195  
risk management strategy 95–6  
Environmental Protection Agency  
(EPA) 16, 64  
European Medicines Agency (EMA);  
see European Medicines  
Evaluation Agency (EMEA)  

David Demortain - 9781849809443  
Downloaded from Elgar Online at 04/13/2019 06:09:01PM  
via free access
Index

epidemiology
combination with toxicology 64
detection of regularities 54
epidemiological surveillance 7, 47, 69, 72, 209
epidemio-surveillance 12
imputation and 62
pharmacoepidemiology and 196
post-market surveillance and 68
safety specification and 80
epistemic community 11, 19–21, 24–6, 28, 35–6, 189
EudraVigilance 96
European Federation of Pharmaceutical Industries and Associations (EFPIA) 102, 178
European food law 43–7, 64, 70, 119, 121, 128, 144
European Food Safety Authority (EFSA); see also regulatory agencies
coordination of surveillance plans 60
creation of 47
data collection mission 47
International Life Science Institute and 161, 206
members of EFSA panels 159, 160, 178
production of risk assessment opinions 47
recommendation on post-market monitoring studies 150
European official guidelines on pharmacovigilance for medicinal products for human use (the ‘Volume 9’) 80
European Parliament 45, 46, 47, 73, 74, 94, 146, 165
evaluation
as science 12, 15, 32, 35, 37, 38, 48, 169, 173, 183
regulation 196, 208
standard-setting and 11, 99, 108
Evans, Stephen 86, 87, 88, 89, 90, 93, 98, 99; see also Waller, Patrick
Expert; see also scientists
coopertation 76, 125, 135, 174, 183
hybridisation of expertise 197
industry advice 33, 132, 139, 187
label of expert 171, 188
prestige 20
quasi-regulators 107, 108, 188
recruitment 131, 134, 135, 158, 182
scientific advice 4, 36, 44, 45, 73, 167, 168, 174, 175, 180, 189
occupationalisation of 174
transnationalisation of experts’ career 177, 181, 188

Federal Food Drug and Cosmetic Act 39
Fischer, F. 206
Food and Agricultural Organization (FAO) 70, 113, 131, 132, 135, 151, 159, 178
Food and Chemical Toxicology (FCT) 142, 143, 147, 149, 155
Food and Drug Administration (FDA) 39, 40, 64, 66, 67, 68, 73, 74, 86, 89, 93, 110, 113, 125, 131, 150
food hygiene
as research area 169, 171
Codex Committee on Food Hygiene 128, 129
consultants 130
criteria 113
dead of chain control 112–14
European Directives 118
food microbiologists and 131
food microbiology and 52, 62
fragmentation of 14
large businesses and 199
liberalisation 198
local regimes 123
performance-based 139
promotion of industrial food hygiene 125
regulation of 1, 12, 201, 202
food microbiology
co-word analysis of 63–4
delit of 131, 134, 169, 170, 173, 189, 202
food regulation and 202
industry support 64, 176
journals of 126
limits of 65
microbiology and 52
Scientists and the regulation of risk

professional jurisdiction of 131
reorientation of 130
food safety; see also risk assessment
food additives 2, 5, 46, 50–51, 60, 61, 62, 68, 69, 74, 147, 151, 159, 162, 176
food surveillance 12, 60, 65
food zoonoses 47
food-borne diseases 39, 136
White Paper on Food Safety 45
functional foods 46, 144–7, 150, 152, 156, 158, 159, 162, 163, 212
functional efficacy 144, 148
Funtowicz, S. and Ravetz, J. 2
Gabriel 99, 102–9, 172, 177, 178, 181, 182, 183, 190, 193, 194, 196
General Agreement on Tariff and Trade (GATT) 70
General Food Law 46, 47, 64, 70, 119, 144; see also European food law; European Food Safety Authority (EFSA)
global knowledge network 19, 23; see also network concept
Gold, Harry 56, 74
guidance
as source 213
for HACCP 113, 114, 116, 125, 126, 128, 131
for PMM 142, 149, 156, 163, 164, 203
for PVP 83
generic guidance 120
inducement of change in industry 103
normative pyramid 150
risk management 99
soft law 18
Haas, P. 20–21, 24–26
Hazard Analysis Critical Control Point (HACCP)
audit and 120, 121
critical control points (CCP) 112, 115, 125, 131, 134–8
critical control points, determination of 127–8
critical failure areas concept and 124
decision-tree 75, 118, 126, 127, 129, 134
developing countries and 136, 209
HACCP-like approaches and systems 112, 113, 123, 139, 140
hazard analysis 115, 122, 123, 127, 136, 149
ISO and 116, 128, 138
local vs. central establishment of critical control points 121–3, 130
logic sequence 116, 117, 129, 134
manuals 35
negotiation of critical control points 123, 139
philosophy 121, 127
policy panacea 115
principles 112
quality assurance 120, 122, 130, 131, 132, 172, 180, 187, 201, 213
regulatory concept 12, 13, 14, 15
reliability 124, 199
risk analysis 199
systems thinking 124, 199
total quality management and 128
translation 136
Heads of Agencies (HOA) 73, 95, 96, 107, 110
Heads of Medicines Agencies (HMA): see heads of agencies (HOA)
Hill, Bradford 56
imputation, research programme of 12, 17, 37–8, 46–7, 52, 55–6, 60, 63–4, 71–2, 76, 202, 213; see also evaluation
Inman, William 56, 67, 86
inspectors
as actors of regulatory intervention 213
as consultants and auditors 121
as regulatory intermediaries 130
complexity of the role of 198, 199
food microbiologists and veterinarians as 202
HACCP plans and external inspectors 113, 120
National Advisory Committee on Microbiological Criteria for Foods (NACMCF) and 126
negotiation with 123, 139

David Demortain - 9781849809443
Downloaded from Elgar Online at 04/13/2019 06:09:01PM via free access
Index

self-control and 119
sharing of information with 9
surveillance of food contaminations 7
training of food inspectors 125
interest groups 24
International Commission for the
Microbiological Safety of Food
(ICMSF) 69, 76, 125–9, 130, 131–5, 137, 139, 176, 177, 178, 181, 183, 186, 198, 201, 207
International Conference of
Harmonisation (ICH) 33, 77, 78, 79, 81, 83, 84, 88, 97–9, 101–5, 107–10, 167, 177, 178, 181, 193, 209; see also Council for the
International Organization of the
Medical Sciences (CIOMS)
International Life Science Institute
interstitial organisations 15, 34, 169, 181–6, 188, 189, 207, 208
invisible college
as club 183, 189
benefits of using the notion of 11, 19, 31–4
big players and 139
embeddedness in regulation 103–4
frontiers 161–3, 204
HACCP principles and 114
history of the 29
junction between evaluation and
standard-setting 11, 99, 108; see also evaluation
manufacturing of consensus 134
occupational diversity in 172
PMM experts as 159
scientometrics and 29–30
Jasanoff, S. 2, 171
Jean-Claude 132, 176–8, 186–8, 199
John 158, 161, 163, 178, 187
Joint Expert Committee for Food
Additives (JECFA) 68, 69, 70, 178
Kefauver, Senator Carey Estes 40
Keohane, R. 21, 25
Knorr-Cetina, K. 26, 27, 27
Koch, Robert 52
Lachance, Paul 124
Lezaun, J. 7
liability 17, 43, 56
life-style medicines 86, 95
Lipobay 43, 97, 110, 153; see also cerivastatin; drug withdrawal
marketing authorisation
as a type of control 47
European Union procedures for
40–43
for food products 46, 68
for novel foods 149, 150, 152
of me-too drugs 86
phytosterol esters 153
positive list and 68
pre-marketing tests 13, 56, 145, 147, 195
revision of 87, 98
submission of risk management plan
and 81
Marks, H. 48, 66, 71, 73
medicines agencies
blaming of 94
Medicines and Health products
Regulatory Agency (MHRA) 73, 76; see also Medicines
Control Agency (MCA)
Medicines Control Product Agency
(MCA) 73, 86, 88, 89, 101, 107, 110, 167, 172, 177, 193, 206
organisation 82, 83, 156
Merck 96, 97
me-too medicine 5, 17, 84, 85, 86, 95
Meyer, J. 192
Michael 132, 140, 172, 176, 177, 178, 186, 199
microbiology
as scientific discipline 176, 201
microbiological risk assessment 37, 65, 69, 199
Ministry of Agriculture, Food and
Fisheries (MAFF) 151, 152
Modell, Walter 74
Mogoutov, Andrei 214
multi-professionalism: see scientists
National Advisory Committee on Microbiological Criteria for Foods (NACMCF) 126, 129, 131, 132, 135
National Aeronautics and Space Administration (NASA) 112, 124, 131, 186, 198, 199
National Research Council (NRC) 3, 64, 70, 126, 166, 199
Nestlé 126, 129, 132, 145, 176
network concept
embedded knowledge network 23
global knowledge network 19, 23
global public policy networks 22
network of professionals 20, 21, 24
transnational policy networks 22
Nicolas 159, 161, 163, 175, 176, 187, 189
non-governmental organisations 20, 161, 210
novel foods
as regulatory domain 1
European novel food regulation 146, 147, 150, 153, 165, 166
experience of 15
pre-market regulation and 46, 68
post-market monitoring and 142, 158–66
regulatory definition 144–52
regulatory terminology 146
research interest 156
researchers in 169
side-effects of 8, 13, 14

Olestra 154
Organisation for Economic Cooperation and Development (OECD) 159, 161, 178

Parmar, I. 23
Pasteur, Louis 52
Patrick 159, 161, 163, 176, 190
Periodic Safety Update Report (PSUR) 98, 99, 102, 195, 196
pharmaceutical industry 41, 49, 67, 102, 179, 182, 207, 211
pharmacoepidemiology 57, 67, 69, 74, 86, 89, 91, 196
pharmacovigilance
additional pharmacovigilance activities 80
audit 82, 87, 96, 196
centralised procedure and 40, 41
definition of 17
drug monitoring 57, 59, 73, 101
French school of pharmacovigilance 43
industrial pharmacovigilance 177, 194, 195, 197
national pharmacovigilance systems 42, 43, 67, 90, 108
pharmacovigilance responsible person 82, 102, 170, 172
public health and 86–8, 92, 93, 97, 98, 99, 103, 107, 196
regulatory philosophy 93
safety databases 35, 64, 65, 75, 83, 90, 194
terminology 102
phase IV studies 43, 81
phocomelia 42, 59, 90; see also adverse drug reaction
phytosterol esters 152–5, 159, 163, 166
Pillsbury 14, 112, 114, 124, 125, 126, 131, 139, 140, 186, 198, 199
post-market monitoring (PMM)
consumer targeting 155
dose exposure 153
exposure assessment guidance for 142–3
International Life Science Institute (ILSI) and 158–63
post-launch monitoring (PLM) and 152, 153, 154–5, 156, 157, 163
post-marketing surveillance (PMS) and 156, 157
reassurance 8, 148
regulatory concept 12, 13, 14, 15, 150–57
risk analysis principle 199–200
risk assessment 143–9, 153, 157, 158
scope 143, 148, 153, 164, 165, 202, 203
policy enterprise 20, 24, 39
Porter, T. 7, 18
post-normal science 2
practolol 55, 91
Price, D. J. de S. 29–31, 34
Procter & Gamble 154
Prodi, Romano 45
pharmaceutical risk management 83, 84, 96, 97, 194, 196
blame avoidance and 94, 96, 99, 106
FDA risk management 95–6
pharmacovigilance planning (PVP) agencies' reorganisation and 79, 82, 83
as research area 169
changes linked to the introduction of 79, 83
data requirements and 80
European Union guideline 81
ICH guideline 79, 80, 81
pre-/post-marketing division 82, 83
pharmaceutical companies' reorganisation and 83, 191
pharmacovigilance specification 12, 78, 79, 81, 88–90, 92, 94, 99, 101, 109, 193, 194
public health and 196
regulatory concept 12, 14, 77–9, 89, 90
risk management and 97, 98, 167
risk management plans 78, 79, 81, 103, 194
risk minimisation 77, 78, 81, 95, 106, 183
risk reduction 196
safety specification 80, 124, 203
physicians
hospital physicians 172, 173
physicians and national pharmacovigilance systems 53–6
physicians and reporting of adverse drug reactions 67, 69, 77, 82, 156, 205
qualification, research programme of 12, 47–53; see also evaluation; imputation
Quorn 151, 152
Rank Hovis McDougall (RHM) 151
Red Book 64
regulatory agencies
agenciﬁcation 206
as nodal point of invisible colleges 205
as risk assessment agencies 6
circulation of scientists and 11
creation of the European Food Safety Authority 47
creation of the European Medicines Evaluation Agency 41
democratic record of regulatory agencies 209–10
sharing of information 9
regulatory authority 157, 181
regulatory concepts 1, 8, 10
as typiﬁcations 5–7
conceptual power 17; see also Carpenter, D.
impact of 191–204
regulatory concepts as objects of research 178, 179
regulatory concepts as standards 11, 35, 189
regulatory space 8, 29
risk 1–8, 16, 75
hazard 2, 46, 60, 63, 64, 65, 75
quantitative dose–response assessment 65
risk analysis as science 2, 3, 16, 17, 60, 64
risk analysis principle 45, 47, 70
risk assessment 2–6, 10, 12, 16, 17, 27, 45, 47, 61, 64–5, 70
risk assessment/risk management terminology 164
risk perception 3
risk regulation
approaches of 17
as set of activities of control 6–7
prioritising risks 3
regulatory failure 15, 84, 98, 192, 196, 197, 206, 207
regulatory rationalisation 212
risk regulation regimes 211
as systems of control 191, 193, 205, 206, 207
Royal Society of London for the improvement of natural knowledge 29, 36
Scientists and the regulation of risk

Royer, René-Jean 58, 93, 105, 173, 174, 183

Sanitary and Phytosanitary Measures (SPS) 70, 116, 129, 140
Santer, Jacques 73, 74, 165
Sauer, Fernand 73, 209
scientific committee for food (SCF) 76, 153, 154, 158, 159, 163, 178
scientific community, concepts of; see also epistemic community; invisible college
community of thought 20
research networks 26
scientific communities 5, 23, 24, 25, 27
thought collectives 25
trans-epistemic arenas 26
scientific disciplines 20, 24, 32, 48
history of scientific disciplines 213
experiments
industry experiments 1, 13, 30, 33, 142, 150, 158, 192, 203, 205
scientific experiments 48, 50, 52, 54, 56, 58, 64, 66, 71, 72
scientists
accumulation of positions 143, 159, 171–2, 178, 180
disciplines and professionalisation of scientists 170, 171, 173, 174, 181
medical scientists 53, 99, 104, 105, 106, 107, 109, 163; see also drug safety scientists
multi-professionalism 11, 169, 191
physicians and 1, 7, 17, 33, 41, 42, 49
professional jurisdiction 168, 195, 196
professional rationalisation 175
professional trajectories of 31, 179
scientific elite 1, 11, 14, 19, 29, 32, 35, 39
social authority 11, 15, 20, 23, 27, 32, 34
training as physicians 172, 173
scientisation 10
rationalisation and 192, 204, 212
Scott, J. 5–7
Selznick, P. 8, 17
Slaughter, A.-M. 21
Society for Risk Analysis (SRA) 16
standardisation
as emergent action 204
boundaries of 158, 164
invisible colleges of 29–34
science-driven 10
standard-setting and 18
standard-setting organisations
as sites of scientists’ circulation 11, 176, 177
drug safety experts and 14, 99, 102, 109
International Life Science Institute (ILSI) as 161
New Approach and 119, 147
statins 17, 84, 85, 86, 92, 93, 98, 153, 195
Stockholm Centre for Organizational Research (SCORE) 10
Stone, D. 23, 28
thalidomide 39–42, 49, 54, 58, 59, 81, 87, 90, 91
theorisation 13, 15
abstraction 13, 158, 201
lesson drawing 13, 89, 96, 107, 109
regulatory modelling 13, 112, 113, 138, 199, 200
toxicology 12, 37, 48–52
allowable daily intake (ADI) 51, 74
dose-response and toxicology 61, 64, 65
food toxicology 50, 52, 64, 65, 68, 69
reference dose 69
relations with industry 64
transboundary risk management 9
transnational
transnational and the global 9
transnational policy networks 22; see also network concept
transnational regulation 10, 11, 19, 22, 123, 134, 181, 188, 208
transnational risk regulation 8, 167
transnationalisation of experts’ career 177, 181, 188
trans-science 2, 37
Truhaut, René 51, 59, 68, 69, 74
uncertainty 2, 3, 12, 20, 26, 27, 37, 48, 52, 54, 59, 64, 71
Index

Unilever 152–6, 158, 159, 163, 166, 187, 203
Uppsala Monitoring Centre (UMC) 92, 101

veterinarians 7, 51, 69, 121, 131, 136, 137, 201, 202
vixxx 43, 96, 110

Weinberg, A. 2
World Health Organization (WHO) contribution to pharmacovigilance planning 86, 89
Council of International Organisation of Medical Sciences and 102, 182

endorsement of HACCP 113, 114, 125, 186
food safety department 136
global food safety challenges 116
International Commission for the Microbiological Safety of Foods and 129, 131, 132, 134, 135
national pharmacovigilance systems and 42, 104, 107
Patrick and 178
quantitative dose-response assessment and 65
risk analysis and 70

World Trade Organization (WTO) 75, 113, 116
Worsley, Benjamin 29